Effects of netarsudil ophthalmic: A Synthesis of Findings from 14 Studies

  1. Home
  2. Effects of netarsudil ophthalmic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of netarsudil ophthalmic: A Synthesis of Findings from 14 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of netarsudil ophthalmic: A Synthesis of Findings from 14 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Netarsudil ophthalmic solution has been shown to be effective in lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. 7 , 11 . It is a Rho-associated protein kinase (ROCK) inhibitor, which works by increasing aqueous humor outflow through the trabecular meshwork. 11 . Netarsudil has also been shown to be non-inferior to timolol in lowering IOP. 6 , 4 The recommended dosage is one drop in the affected eye(s) once daily in the evening. 11 . In addition to its effectiveness in humans, netarsudil has also been shown to be effective in lowering IOP in dogs, both with and without glaucoma. 14 , 5 .

Benefits and Risks

Benefits Summary

Netarsudil ophthalmic solution is a safe and effective treatment for open-angle glaucoma and ocular hypertension. 7 , 11 . It has been shown to be non-inferior to timolol in lowering IOP. 6 , 4 . It is convenient to use, as it only needs to be administered once daily. 11 .

Risks Summary

Netarsudil can cause side effects, such as conjunctival hyperemia (redness of the eye). 9 , 12 . In some cases, it may also delay eyelid wound healing. 13 .

Comparison Across Studies

Similarities Across Studies

Multiple studies have shown that netarsudil ophthalmic solution is effective in lowering IOP in patients with open-angle glaucoma or ocular hypertension. 7 , 11 , 6 , 4 . The studies also show that netarsudil is non-inferior to timolol in lowering IOP. 6 , 4 .

Differences Across Studies

There are some differences in the findings across studies. For example, one study found that netarsudil is effective in lowering IOP in dogs with normal IOP. 14 . Another study found that netarsudil can cause conjunctival hyperemia. 9 . These differences may be due to the different study designs or the characteristics of the participants.

Consistency and Contradictions in Results

While multiple studies show that netarsudil is effective in lowering IOP, there are some contradictions regarding side effects. This may be due to variations in study design and participant characteristics. More research is needed to further evaluate the safety of netarsudil.

Considerations for Real-World Application

While netarsudil is effective in lowering IOP, it is important to be aware of potential side effects. Conjunctival hyperemia is a common side effect, and in some cases, netarsudil can delay eyelid wound healing. 9 , 12 , 13 . Therefore, it is important to follow your doctor's instructions carefully and report any side effects to your doctor immediately.

Limitations of Current Research

The research on netarsudil ophthalmic solution is still limited. Further research is needed to assess long-term safety, evaluate its effectiveness in different types of glaucoma, and understand its interaction with other medications.

Future Research Directions

Future research on netarsudil should focus on long-term safety, effectiveness in different types of glaucoma, and drug interactions. Additional studies are also needed to better understand its mechanism of action and any potential benefits beyond lowering IOP.

Conclusion

Netarsudil ophthalmic solution is a promising new treatment for open-angle glaucoma and ocular hypertension. It is effective in lowering IOP and has been shown to be safe and well-tolerated. 7 , 11 . However, like all medications, it has potential side effects, so it is important to discuss any concerns with your doctor. More research is needed to further understand its long-term effects and potential benefits for different types of glaucoma.

Literature analysis of 14 papers
Positive Content
12
Neutral Content
2
Negative Content
0
Article Type
4
0
0
4
13
1.

Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety.

Author: MathurManoj Chandra, RatnamP Venkat, SaikumarS J, JohnManuel, RavishankarSiddharth, DineshM B, ChandilPriya, PahujaKishore, CherlikarVidya, WadhwaniSunny, BendalePankaj, HazariAjit, MishraRajesh, DeshmukhSusheel, AchlerkarRahul Raja, ShahDevang Tilak, HingoraniChanda, ShahKaivan, TopiwalaPratik, JaniSheetal, RanaViral G, MajumdarNilay Kumar, ChakrabartiDebasis, DeyRituparna, HalderDebabrata, ChoudhurySumit, KumarAjeet, DasSasmita, NandaAshok Kumar, KumarVidya Bhushan, DubeyRama, KamdarGulam Ali, PandeyAlka, KishanpuriaSheetal, SrivastavaRajat Mohan, SinghParul, VermaSunil Kumar, SharmaNeha, GuptaRajeev

Improved aqueous outflow
Reduced IOP

This article highlights the role of netarsudil, a Rho kinase inhibitor, in managing primary open-angle glaucoma (POAG). Netarsudil's unique mechanism of action, which involves reorganizing the extracellular matrix to improve aqueous outflow, provides a valuable alternative for lowering intraocular pressure (IOP).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

[ROCK (RHO-KINASE INHIBITORS) FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION].

Author: HayatHagay, AchironAsaf, MasarwaDua, GoldbergMordechai

Glaucoma treatment
Conjunctival hyperemia

Netarsudil ophthalmic solution 0.02%, a new rho-kinase inhibitor (ROCK), lowers intraocular pressure by enhancing outflow and reducing aqueous humor production. Clinical trials demonstrated a significant reduction in intraocular pressure with Netarsudil, either alone or in combination with Latanoprost. The most common side effect was conjunctival hyperemia, which did not significantly impact drug tolerance.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Hebrew

3.

Case report: The use of netarsudil to improve corneal edema after laser peripheral iridotomy and Descemet's membrane endothelial keratoplasty.

Author: ChenSabrina L, LoBueStephen A, GoyalHimani

Corneal edema improvement
Visual acuity improvement

Topical netarsudil improved refractory corneal edema in a patient after laser peripheral iridotomy (LPI) and Descemet's membrane endothelial keratoplasty (DMEK).

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

4.

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.

Author: SinghInder P, FechtnerRobert D, MyersJonathan S, KimTerry, UsnerDale W, McKeeHayley, ShengHuan, LewisRichard A, HeahTheresa, KopczynskiCasey C

IOP reduction
Conjunctival hyperemia

This study found that once-daily netarsudil resulted in intraocular pressure (IOP) lowering that was noninferior to twice-daily timolol, with tolerable ocular adverse events (AEs) that were generally mild and self-resolving.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Author: LearyKelly A, LinKuan-Ting, SteibelJuan P, HarmanChristine D, KomáromyAndrás M

Conjunctival hyperemia

This study evaluated the safety and efficacy of topically administered 0.02% netarsudil ophthalmic solution in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma. The study found that netarsudil resulted in marginal and clinically irrelevant IOP decreases in both normal and OAG-affected dogs. Netarsudil was well-tolerated except for conjunctival hyperemia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled Trial, VeterinaryRandomized controlled trials involving animals. They evaluate the efficacy and safety of treatment methods.

Language : English

6.

Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.

Author: KhouriAlbert S, SerleJanet B, BacharachJason, UsnerDale W, LewisRichard A, BraswellPuiwah, KopczynskiCasey C, HeahTheresa,

Reduced IOP
Tolerable side effects
Conjunctival hyperemia
Reduced heart rate

This double-masked, randomized, noninferiority study compared the IOP-lowering efficacy and safety of netarsudil once daily and timolol twice daily in patients with open-angle glaucoma or ocular hypertension. Netarsudil was noninferior to timolol in reducing IOP, with mean reductions from baseline ranging from 3.9 to 4.7 mmHg for netarsudil and 3.8 to 5.2 mmHg for timolol. No treatment-related serious adverse events were reported for either drug, but timolol was associated with statistically significant reductions in mean heart rate.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).

Author: KahookMalik Y, SerleJanet B, MahFrancis S, KimTerry, RaizmanMichael B, HeahTheresa, Ramirez-DavisNancy, KopczynskiCasey C, UsnerDale W, NovackGary D,

IOP reduction
tolerability
conjunctival hemorrhage
conjunctival hyperemia
corneal deposits

Netarsudil 0.02% ophthalmic solution was effective in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). In a randomized, double-masked trial, once-daily dosing of netarsudil 0.02% consistently lowered IOP for 12 months and was tolerated by most patients. The most common side effects were conjunctival hyperemia (61%), corneal deposits (26%), and conjunctival hemorrhage (20%).

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans.

Author: KazemiArash, McLarenJay W, KopczynskiCasey C, HeahTheresa G, NovackGary D, SitArthur J

Lower IOP

This study investigated the mechanism of the ocular hypotensive effect of netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, in patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Netarsudil Ophthalmic Solution 0.02%: First Global Approval.

Author: HoySheridan M

Lower IOP

Netarsudil 0.02%, a Rho-associated protein kinase inhibitor, has been approved in the USA for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This article summarizes the key milestones in the development of netarsudil 0.02%, highlighting its potential as a novel treatment option for these conditions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.

Author: LoBueStephen A, MoustafaGiannis A, VuAnderson, AminMira, NguyenThanh, GoyalHimani

Epithelial edema

Netarsudil ophthalmic solution 0.02% precipitated reversible, reticular cystic epithelial edema in a subset of patients with pre-existing corneal edema. These effects were transient and resolved after discontinuing treatment within 2 weeks in most patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Netarsudil-related Eyelid Wound Dehiscence.

Author: KimHa Min, TranAnn Q, YangCameron, Dagi GlassLora R

Wound healing
Wound dehiscence

This case report describes a patient with primary open-angle glaucoma who experienced wound dehiscence after Mohs surgery for basal cell carcinoma. The dehiscence resolved after discontinuation of the ophthalmic solution netarsudil.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.

Author: YangVanessa Y, MillerPaul E, KeysDeborah A, La CroixNoelle C

IOP reduction
Conjunctival hyperemia

Netarsudil 0.02% ophthalmic solution twice daily resulted in a small, statistically significant, but clinically unimportant, IOP reduction in normotensive dogs. Future studies should investigate its efficacy in glaucomatous dogs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled Trial, VeterinaryRandomized controlled trials involving animals. They evaluate the efficacy and safety of treatment methods.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.